We identified two monoclonal antibodies that bind spatially distinctepitopeson insulin-likegrowthfactor I (IGF-l). Using these two antibodies, we developed a simultaneous, two-site immunoradiometncassay (IRMA) specificfor IGF-l. This IRMA has no detectable cross reactivity with insulin, proinsulin, prolactin,or somatotropin,and less than 2% crossreactivity with IGF-lI. The assay response varies linearly with IGF-l concentrationsof 0-800 ig/L in serum;the detectionlimitis about 10 1zg/L.A comparisonof 26 IGF-l serumvalues from the IRMAand from a previouslyreported IGF-I specific RIA gave a correlationcoefficientof 0.96 with no substantialbias (slope = 1.10). IGF-l valuesfor serum,as an aid in assessing growth abnormalities,are easily (only three pipettingsteps) obtained in <4 h. The availability of specific polyclonal antisera (7), and, more recently, monoclenal antibodies (MAbs) (20) (21) (22) , has permitted the development of liquid phase, competitive inhibition RIAs (7, 14-16,
in coiijunction with somatotropin measurement, IGF-I concentrations can provide a valuable laboratory tool in differentiating the pathological conditions that produce growth abnormality (13) . - (17) and radioreceptor assays (18, 19) , but these are impractical for routine use in clinical laboratories.
Nevertheless
The availability of specific polyclonal antisera (7), and, more recently, monoclenal antibodies (MAbs) (20) (21) (22) , has permitted the development of liquid phase, competitive inhibition RIAs (7, 14-16,
20-22).
Generally, however, these assays have been complicated by lengthy incubations, multiple steps, variable specificities, and tedious extraction procedures that usually necessitate neutralization or evaporation and reconstitution of the extracted samples (14) .
Here, we describe a unique set of MAbs, which we have used to developa monoclonal-antibody-based immunoradiometric assay (IRMA) for IGF-I. This assay has the advantages of short incubation, ease of performance, and <2.0% crossreactivity with IGF-ll. Because of its low detection limit, this assay alsopermits simplification ofthe extraction procedure.
MaterIals and Methods
Isolation and purification of recombinant hIGF-I: Purified, bioactive methionine-hIGF-I was prepared from specifically constructed Escherichia coli strains as previously described (23) . This compound is biochemically identical to endogenous hIGF-I except for an additional methionine residue at the N-terminus, the result of its bacterial expression. We established the purity and homogeneity of the preparation by standard methods of protein characterization, including electrophoresis on sodium dodecyl sulfatepolyacrylamide gel, isoelectric focusing, amino acid analysis, size-exclusion chromatography, and reversed-phase liquid chromatography.
The purified methionine-hIGF-I bound specifically, with high affinity (ED50 = 1.1 ng), to IGF receptors in a human placental membrane radioreceptor assay (19).We found this preparation to be biologically and immunologically identical to endogenous hIGF-I when examined in other polyclonal antiserum-based RIAs and in other receptor assays (24 spatially distinct epitopes. We performed standard fusion methods three days after the last booster ujection, which was given in isotonic saline (25) . Selected cell lines were cloned by limiting dilution, after which hybridoma cultures were expanded and injected into BALBIc retired breeders for ascites production.
The MAbs were further purified by "high-performance" ion-exchange chromatography on a Protein-Pak diethylaminoethyl 5PW column (Waters Associates, Milford, MA) after which we could iodinate them (10-20 CiJg) by a modification of the Chloramine T method (26) or could use them to coat solid surfaces.
MAb characterization:
The specificity of selected antibodies was determined in a competitive-inhibition RIA done on a microtiter plate as previously described (27) . Briefly, the procedure is as follows. We coated 96-well, flexible polyvinyl-chloride microtiter plates (Falcon Plastics, Lincoln Park, NJ) with purified anti-IGF-I MAbs and tested various proteins as inhibitors of 'I-labeled methionine-hIGF-I binding. Inhibition by these proteins was compared with that by methionine hIGF-I standards to estimate cross reactivity.
The ability of different MAbs to bind IGF-I simultaneously was determined by an inhibition assay in which two MAbs were allowed to compete for soluble lmIlabeled methionine-hIGF-I. We determined the approximate affinity of these monoclenal antibodies as previously described (28).
Protein standards: After confirming the concentration of methionine-hIGF-I by amino acid analysis we prepared methionine-hIGF-I standards in a matrix containing, per liter, 10 mmol of phosphate, 150 mmol of NaC1, 10 g of bovine serum albumin, and 20 000 USP units of heparin (pH 7.4). All bovine serum albumin used in these procedures was screened for the absence of IGF-I. Threonine59-hIGF-I was purchased from Amgen, Thousand Oaks, CA, so we could examine the immunoreactivity of another recombinant hIGF-I preparation. Natural hIGF-I isolated from human plasma was kindly provided by Dr. R. Humbel (5). Bacterial recombinant IGF-il was kindly provided by Dr. D. Harlem (Biogen S. A., Geneva, Switzerland). Purified human prolactin and somatotropin were purchased from Calbiochem, La Jolla, CA; human insulin was purchased from Sigma Chemical, St. Louis, MO; and human proinsulin was a gift from Dr. H. Tager, The University of Chicago.
Serum samples: Serum samples from patients with growth disorders were obtained from the Radioimmunoassay Core Laboratory in the Diabetes Research and Training Center at Washington University. IGF-I determinations had been performed in the laboratory, after acidethanol extraction by a previously published double-antibody RIA (13, 14).
Extraction procedure: Interference from binding proteins in serum was eliminated by extracting sera with a modification of a previously published acid-ethanol procedure (14). Briefly, 500 pL of a solution ("extraction buffer") containing 850 mL of ethanol and 0.25 mol of formic acid per liter was added to 50 pL of serum and incubated at room temperature for 30 mm. Sample tubes were then centrifuged for 10 mm at 1000 x g. We used 25 pL of the supernate in the assay directly, without evaporation or neutralization.
IRMA assay: We developed the IGF-I-speciflc IRMA by modifying previously described methods involving MAbs (29) . To a polystyrene tube (Maxisorb; NUNC, Thousand Oaks, CA) to which 2.5 pg of MAb 6B1.1 had been passively adsorbed we add 2 x i0 counts/mm of 'I-labeled MAb 2D12.1, in 1 mL of assay buffer (pH 7.4), which contains 100 mmol of sodium phosphate, 150 mmol of NaC1, 300 USP units ofheparin, 1.0 mL ofTween 20, and 1 g ofEDTA per liter. We include heparmn in the assay because of previous reports that it improves analytical recovery of IGF-I from binding proteins (16). Without delay, we then add 25 L of extracted serum supernate or standard (unextracted) to the tube and incubate at 37 #{176}C for 3 h. We then decant samples from the tubes, wash the tubes three times with water, and count the bound radioactivity remaining.
IGF-I concentrations are determined by comparing the counts bound in the sample tubes with those for the standard curve.
Results

Characterization
of MAbs: Evidently the two MAbs, 6B1.1 and 2D12.1, bind spatially distinct epitopes, because neither antibody in the liquid phase inhibited methionine-hIGF-I binding by the other solid-phase antibody (data not shown). Each antibody completely inhibited its own solid-phase binding. Both antibodies were shown to have high binding affinities: Ka = 2 x iO L/mol for 6B1.1 and 6 x i08 L/mol for 2D12.1 (data not shown).
The specificity of these two antibodies was determined by inhibition RIA. Table 1 shows the concentration of various proteins that inhibited 50% of maximal binding of 'I labeled human methionine-IGF-I by the two antibodies. Human somatotropin and prolactmn exhibited no detectable cross reactivity with either antibody. MAb 6B1.1 exhibits 21% cross reactivity with IGF-H; MAb 2D12.1 has <1.2% cross reactivity with IGF-ll in this assay. Both antibodies bind natural hIGF-I and threonine5g-IGF-I.
Differences in the potency and apparent cross reactivity observed with the two other IGF-I preparations may be ascribable to differences in the actual concentrations of the preparations, because the slopes of the inhibition curves were virtually identical. In the double-antibody RIA the potency of the natural hIGF-I was 70% that of the threornne59-IGF-I preparation (data not shown). It is also conceivable that some immunological differences exist because these MAbs were raised against methionine-hIGF-I, which was also used as the labeled ligand and for preparation of the standards.
IRMA standard curve and cross reactivity. The hIGF-I mr standard curve is essentially linear from 0 to 800 g/L and the minimum detectable dose in serum is 10 ,ug/L (>3 SD above the 0 zg/L standard) (Figure 1) . We prepared the IRMA standards so that the actual concentrations were 11 times less than stated, to duplicate the 11-fold dilution in the serum extraction procedure and to allow direct use of the standards without dilution. Thus, 22 pg is the actual amount of IGF-I present in the tube at the limit of detection. No high-dose inhibition of count rates ("hook effect") was observed with standards in concentrations as high as 4 mg/L. When we added 25 .tL of extraction buffer to the standard tubes we saw no change in the count rates (data not shown). Linear regression analysis of this standard curve demonstrated a correlation coefficient (r) of 0.99, and coefficients of variation (CV) ranged from 3.3% to 10% for the various standard concentrations.
We observed no cross reactivity with insulin or pro-insulin. However, we found IGF-ll to cross react by 1.6% with methiomne IGF-I in the nm (Table 2) .
IRMA assay performance: Analytical recoveries of methionine-IGF-I added to sera from five patients ranged from 76% to 103% (Table 3) . Intra-assay CVs for five patients' sera were 2.5% to 7.8%; interassay CVs were 1.8% to 14% (Table  4) . Natural and Amgen IGF-I gave values that were 39% and 136%, respectively, of the stated concentrations (Table  2 ), in agreement with results from the inhibition RIAs (Table 1) .
Serum samples from 26 patients, with RLA values covering a wide analytical range (25-1008 pgfL), were run in both the IRMA and REA (Figure 2 ). Linear regression analy-
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Cross reactlvlty,#{176} 10 (y = 1.1(r -4.5) . When seven samples with values >200 pg/L in the RIA were assayed in the IRMA without extraction we found the relation y = 0.64x + 302 (r = 0.55), and recoveries averaged 52% as compared with the RIA. This demonstrates that the extraction procedure is needed.
Discussion
This two-site, monoclonal-antibody ll'MA is specific for methionine-IGF-I, and it possesses all of the advantages inherent to the two-site reMA configuration: simultaneous incubation, ease of performance, linear standard curve, and short incubation intervals (29) . Furthermore, because we were able to identif' a MAb (2D12.1) with no apparent cross reactivity with IGF-ll, the assay has exquisite specificity for IGF-I. This is particularly important because IGF-H concentrations in serum are three to four times greater than those of IGF-I (30).
MAb 2D12.1 appears to have less cross reactivity (<1.2%) Possibly because we immunized with free methionine-IGF-I, instead of coupling it with a carrier protein as previous investigatore have done, we were fortunate enough to identif' two MAbs capable of binding to IGF-I simultaneously, which allowed the development of the two-site IRMA configuration.
There may be some differences in immunoreactivity between human-origin methiomne-IGF-I, threonine59-IGF-I, and natural IGF-I with these MAbs (Tables 1 and 2 ). However, we believe the observed differences are probably due to differences in the actual concentration of the starting material and not to different immunological properties.
The natural IGF-I preparation has been stored for several years at -70 #{176}C and had only 70% of the potency of the threenine59-hIGF-I in the double-antibody RIA. Furthermore, the excellent correlation and recoveries seen between the IRMA and the RIA argue against possible immunological differences. Nevertheless, the methionine-IGF-I has an extra methionine at the N-terminus; otherwise the sequence is identical to natural IGF-I, and we cannot rule out a possible effect of this on epitope expression. Conceivably, there are differences in tertiary structure between the recombinant IGF-I and natural IGF-I because of the bacterial origin of methionine-IGF-I.
Interestingly, the methiomne-IGF-I was also more potent than natural IGF-I in a monoclonalantibody-based inhibition RIA, but not in a polyclonal-based RIA (24) . Nevertheless, the Amgen threonine59-IGF-I lacks this N-terminal methionine, but differs from natural IGF-I by a threonine-for-methiomne substitution at residue 59. Thus, one would expect it to also show decreased immunoreactivity, similar to natural human IGF-I, if the N-terminal methionine was indeed affecting epitope expression. Further work will be required to fully address this question.
For our IGF-I nua we could demonstrate excellent recoveries, precision, and reproducibility.
Despite the high afilnities of the MAbs used in the assay, we found that it is still necessary to release IGF-I from the binding proteins in a manner similar to other immunoassays (13, 14) . However, because of the sensitivity of this assay, it requires only 25 zL of extracted sample, without the necessity for columns, neutralization, or evaporation and reconstitution after extraction. With this assay, values for IGF-I in serum are steps.
The clinical value of IGF-I measurement is based on several observations. First, it is known that IGF-I is the effector molecule for many somatotropin-mediated growth events (31) . For instance, cartilage sulfation, [3H]thymidine uptake, and weight gain can be observed, appropriately, in vitro or in vivo in the absence of somatotropin.
Secondly,
IGF-I concentrations
reflect somatotropin action. Thus, the concentration of IGF-I is increased in acromegaly, is often decreased in pituitary dwarfism, and can correlate with rate of growth in the latter condition (10-13, 
33).
However, because normal values for IGF-I in serum are age dependent, vary widely within age groups, and are influenced by other factors beside somatotropin, care must be exercised in interpreting results (34) . For instance, in the first few postnatal years, IGF-I values are normally low and overlap considerably with those obtained for somatotropin-deficient children (35) . Furthermore, IGF-I concentrations increase dramatically during puberty, and measurements must take into account pubertal stage as well as age (35) .
When used in conjunction with dynamic and provocative somatotropin measurements, IGF-I values can be used to differentiate 
